文献速递白血病淋巴瘤

Hyper-CVAD联合序贯贝林妥欧单抗±奥加伊妥珠单抗治疗新诊断费城染色体阴性B细胞急性淋巴细胞白血病年轻成人

Hyper-CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.
PubMed 文献 · Am J Hematol · 2025-01-05

研究纳入75例新诊断费城染色体阴性B细胞急性淋巴细胞白血病年轻成人(中位年龄33岁),接受最多4周期Hyper-CVAD后4周期贝林妥欧单抗;自第39例起加用奥加伊妥珠单抗0.3 mg/m2(第1、8天)于两周期大剂量甲氨蝶呤和阿糖胞苷及两周期贝林妥欧单抗。加用奥加伊妥珠单抗组3年无复发生存率90% vs 未加用组74%(p=0.06),3年总生存率100% vs 82%(p=0.01)。

要点

  • 加用奥加伊妥珠单抗组3年无复发生存率90% vs 未加用组74%(p=0.06)。
  • 加用奥加伊妥珠单抗组3年总生存率100% vs 未加用组82%(p=0.01)。
  • 队列2中79%患者达到二代测序可测量残留病阴性(灵敏度1×10-6),未观察到肝窦阻塞综合征。

核心结论

  • Hyper-CVAD联合贝林妥欧单抗及奥加伊妥珠单抗改善了新诊断B-ALL患者的结局。

研究设计与样本

  • 研究纳入75例新诊断费城染色体阴性B细胞急性淋巴细胞白血病患者,中位年龄33岁(范围18-59岁)。
  • 患者接受最多4周期Hyper-CVAD后4周期贝林妥欧单抗;自第39例起,奥加伊妥珠单抗0.3 mg/m2于第1、8天加入两周期大剂量甲氨蝶呤和阿糖胞苷及两周期贝林妥欧单抗。
  • 主要终点为无复发生存率。

主要发现

  • 75例患者中37例(49%)接受Hyper-CVAD联合贝林妥欧单抗及奥加伊妥珠单抗(队列2)。
  • 队列2中79%患者达到二代测序可测量残留病阴性(灵敏度1×10-6)。
  • 整体中位随访44个月(范围13-90),队列2中位随访26个月(范围8-39)。
  • 整个队列估计3年无复发生存率82%,3年总生存率90%。
  • 接受与未接受奥加伊妥珠单抗组3年无复发生存率分别为90% vs 74%(p=0.06),3年总生存率分别为100% vs 82%(p=0.01)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adding inotuzumab ozogamicin (InO) to hyper-CVAD and blinatumomab may improve outcomes in newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (B-ALL). Patients with newly diagnosed B-ALL received up to four cycles of hyper-CVAD followed by four cycles of blinatumomab. Beginning with patient #39, InO 0.3 mg/m2 was added on Days 1 and 8 to two cycles of high-dose methotrexate and cytarabine, and two cycles of blinatumomab. The primary endpoint was the relapse-free survival (RFS) rate. Seventy-five patients were treated (median age of 33 years; range, 18-59), of whom 37 (49%) received hyper-CVAD with blinatumomab and InO (cohort 2). Measurable residual disease (MRD) negativity by next-generation sequencing (sensitivity: 1 × 10-6) was achieved in 79% of patients in cohort 2. The median follow-up was 44 months (range, 13-90) overall, and 26 months (range, 8-39) in cohort 2. For the entire cohort, the estimated 3-year RFS rate was 82% and the 3-year overall survival rate was 90%. These rates were 90% versus 74% (p = 0.06) and 100% versus 82% (p = 0.01) in patients who did or did not receive InO, respectively. No sinusoidal obstruction syndrome was observed. In summary, hyper-CVAD with blinatumomab and InO improved the outcomes of patients with newly diagnosed B-ALL.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Kantarjian H, Short NJ, Jain N, et al. Hyper-CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Am J Hematol. 2025. PMID: 39757533. doi:10.1002/ajh.27576

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。